GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Misonix Inc (NAS:MSON) » Definitions » EBITDA

Misonix (Misonix) EBITDA : $-6.15 Mil (TTM As of Jun. 2021)


View and export this data going back to 2019. Start your Free Trial

What is Misonix EBITDA?

Misonix's EBITDA for the three months ended in Jun. 2021 was $-2.20 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Jun. 2021 was $-6.15 Mil.

During the past 3 years, the average EBITDA Growth Rate was -59.50% per year. During the past 5 years, the average EBITDA Growth Rate was -20.10% per year. During the past 10 years, the average EBITDA Growth Rate was -35.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Misonix was 71.00% per year. The lowest was -76.60% per year. And the median was -18.45% per year.

Misonix's EBITDA per Share for the three months ended in Jun. 2021 was $-0.13. Its EBITDA per share for the trailing twelve months (TTM) ended in Jun. 2021 was $-0.36.

During the past 3 years, the average EBITDA per Share Growth Rate was -28.60% per year. During the past 5 years, the average EBITDA per Share Growth Rate was -2.10% per year. During the past 10 years, the average EBITDA per Share Growth Rate was -25.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Misonix was 60.60% per year. The lowest was -70.30% per year. And the median was -11.00% per year.


Misonix EBITDA Historical Data

The historical data trend for Misonix's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Misonix EBITDA Chart

Misonix Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.53 -1.51 -5.69 -15.77 -6.15

Misonix Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.42 -2.92 0.80 -1.83 -2.20

Competitive Comparison of Misonix's EBITDA

For the Medical Devices subindustry, Misonix's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Misonix's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Misonix's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Misonix's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Misonix's EBITDA for the fiscal year that ended in Jun. 2021 is calculated as

Misonix's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Jun. 2021, Misonix's EBITDA was $-6.15 Mil.

Misonix's EBITDA for the quarter that ended in Jun. 2021 is calculated as

Misonix's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Jun. 2021, Misonix's EBITDA was $-2.20 Mil.

EBITDA for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Misonix  (NAS:MSON) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Misonix EBITDA Related Terms

Thank you for viewing the detailed overview of Misonix's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Misonix (Misonix) Business Description

Traded in Other Exchanges
N/A
Address
1938 New Highway, Farmingdale, NY, USA, 11735
Misonix Inc is a medical devices company. It designs, manufactures, markets, and sells invasive surgical ultrasonic medical devices. The company's products enhance clinical outcomes and provide value to the overall healthcare system. It has developed products such as BoneScalpel, NeXus, Sequel, SonaStar, SonicOne, Theragenesis, TheraSkin, and Therion. These products are used for precise bone sculpting, removal of soft and hard tumors, tissue debridement, primarily in the areas of neurosurgery, orthopedic surgery, plastic surgery, wound care, and maxillo-facial surgery. The company generates revenue from various regions that include the United States, the United Kingdom, the European Economic Area, Asia and the Asia Pacific, and South America.
Executives
Paul A Laviolette director ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Sharon W Klugewicz officer: Chief Operating Officer 3661 HORSEBLOCK ROAD, MEDFORD NY 11763
Thomas M Patton director C/O OSTEOTCH INC., 51 JAMES WAY, EATONTOWN NJ 07724
Joseph P Dwyer officer: Chief Financial Officer 3 CORDWOOD COURT, E. NORTHPORT NY 11731
Gwendolyn A Watanabe director C/O SARATOGA VENTURES, 210 ALMENDRA AVENUE, LOS GATOS CA 95030
Linwood A. Staub officer: Sr. VP Wound 8023 VANTAGE DRIVE SAN ANTONIO TX 78230
Stavros G. Vizirgianakis director, officer: CEO 1/16-18 TENNYSON ST., WILLIAMSTOWN NORTH, VICTORIA CA 3016
Robert S Ludecker officer: SVP Sales - Surgical 4 WILDBRIAR COURT MOUNT SINAI NY 11766
Allan Richard Staley officer: President C/O SOLSYS MEDICAL, LLC 600 THIMBLE SHOALS BLVD., SUITE 200 NEWPORT NEWS VA 23606
Michael Koby director C/O 1315 CAPITAL 2929 WALNUT STREET, SUITE 1240 PHILADELPHIA PA 19104
1315 Capital Management, Llc 10 percent owner 2929 WALNUT STREET SUITE 1240 PHILADELPHIA PA 19104
Sv Life Sciences Fund Vi (gp), L.p. 10 percent owner ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Svlsf Vi, Llc 10 percent owner ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Sv Life Sciences Fund Vi Strategic Partners, L.p. 10 percent owner C/O SV LIFE SCIENCES ADVISERS, LLC, ONE BOSTON PLACE, SUITE 3900, BOSTON MA 02108
1315 Capital, L.p. 10 percent owner 3020 MARKET STREET, SUITE 104 PHILADELPHIA PA 19104

Misonix (Misonix) Headlines

From GuruFocus

Misonix Receives Health Canada Approval for neXus

By Marketwired Marketwired 03-04-2021